Provision of HIV viral load testing services in Zimbabwe: Secondary data analyses using data from health facilities using the electronic Patient Monitoring System.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
11
01
2020
accepted:
02
12
2020
entrez:
22
1
2021
pubmed:
23
1
2021
medline:
16
6
2021
Statut:
epublish
Résumé
Routine viral load (VL) testing among persons living with Human Immunodeficiency Virus (PLHIV) enables earlier detection of sub-optimal antiretroviral therapy (ART) adherence and for appropriate management of treatment failure. Since adoption of this policy by Zimbabwe in 2016, the extent of implementation is unclear. Therefore we set out to determine among PLHIV ever enrolled on ART from 2004-2017 and in ART care for ≥12 months at health facilities providing ART in Zimbabwe: numbers (proportions) with VL testing uptake, VL suppression and subsequently switched to 2nd-line ART following confirmed virologic failure. We used retrospective data from the electronic Patient Monitoring System (ePMS) in which PLHIV on ART are registered at 525 public and 4 private health facilities. Among the 392,832 PLHIV in ART care for ≥12 months, 99,721 (25.4%) had an initial VL test done and results available of whom 81,932 (82%) were virally suppressed. Among those with a VL>1000 copies/mL; 6,689 (37.2%) had a follow-up VL test and 4,086 (61%) had unsuppressed VLs of whom only 1,749 (42.8%) were switched to 2nd-line ART. Lower age particularly adolescents (10-19 years) were more likely (ARR 1.34; 95%CI: 1.25-1.44) to have virologic failure. The study findings provide insights to implementation gaps including limitations in VL testing; low identification of high- risk PLHIV in care and lack of prompt utilization of test results. The use of electronic patient-level data has demonstrated its usefulness in assessing the performance of the national VL testing program. By end of 2017 implementation of VL testing was sub-optimal, and virological failure was relatively common, particularly among adolescents. Of concern is evidence of failure to act on VL test results that were received. A quality improvement initiative has been planned in response to these findings and its effect on patient management will be monitored.
Identifiants
pubmed: 33481931
doi: 10.1371/journal.pone.0245720
pii: PONE-D-20-00956
pmc: PMC7822242
doi:
Substances chimiques
Anti-Retroviral Agents
0
Types de publication
Clinical Trial
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0245720Subventions
Organisme : FIC NIH HHS
ID : D43 TW009539
Pays : United States
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
BMC Infect Dis. 2017 May 3;17(1):326
pubmed: 28468608
MMWR Morb Mortal Wkly Rep. 2016 Dec 02;65(47):1332-1335
pubmed: 27906910
PLoS One. 2019 Feb 5;14(2):e0211326
pubmed: 30721229
Int Health. 2017 Jul 1;9(4):206-214
pubmed: 28810670
J Int AIDS Soc. 2014 Jan 15;17:18646
pubmed: 24433983
N Engl J Med. 2016 Sep 1;375(9):830-9
pubmed: 27424812
AIDS Res Ther. 2017 Jan 19;14(1):3
pubmed: 28103895
PLoS One. 2015 Feb 19;10(2):e0116144
pubmed: 25695494
BMC Infect Dis. 2019 Jan 3;19(1):8
pubmed: 30606128
BMC Infect Dis. 2017 Aug 22;17(1):582
pubmed: 28830382
PLoS One. 2014 Jan 29;9(1):e86305
pubmed: 24489714
J Int AIDS Soc. 2017 Jul 19;20(1):21803
pubmed: 28777506
Lancet HIV. 2015 Jul;2(7):e271-8
pubmed: 26423252
N Engl J Med. 2013 Nov 7;369(19):1807-18
pubmed: 24195548
PLoS One. 2018 Jan 11;13(1):e0190659
pubmed: 29324811
South Afr J HIV Med. 2017 Mar 31;18(1):696
pubmed: 29568632
Nature. 2015 Dec 3;528(7580):S68-76
pubmed: 26633768
PLoS Med. 2019 May 29;16(5):e1002820
pubmed: 31141516
PLoS One. 2018 May 1;13(5):e0196259
pubmed: 29715323
J Adolesc Health. 2014 Feb;54(2):121-38
pubmed: 24182940